Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 2 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 12344677

    Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  2. US 12344654

    Mage A4 T cell receptors

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  3. US 12344665

    Treatment of fibrodysplasia ossificans progressiva by administration of an anti-activin a antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  4. US 12338199

    Bis-octahydrophenanthrene carboxamides and protein conjugates thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  5. US 12338274

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  6. US 12337199

    Stable antibody formulation

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  7. US 12331127

    Therapeutic uses of anti-GITR antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  8. US 12331109

    Antigen binding molecule formats

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  9. US 12331099

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  10. US 12325752

    Immunoglobulin proteins that bind to NPR1 agonists

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 10, 2025 · Expires Jun 5, 2045

    granted
  11. US 12319724

    IL2 agonists and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  12. US 12319728

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  13. US 12317874

    Method of using a genetically modified mouse that expresses human albumin

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  14. US 12304969

    Factor XI A2 domain-binding antibodies and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted May 20, 2025 · Expires May 15, 2045

    granted
  15. US 12297207

    Maytansinoid derivatives, conjugates thereof, and methods of use

    REGENERON PHARMACEUTICALS, INC. · Granted May 13, 2025 · Expires May 8, 2045

    granted
  16. US 12297279

    Compositions and methods for treating pain in subjects with rheumatoid arthritis

    REGENERON PHARMACEUTICALS, INC. · Granted May 13, 2025 · Expires May 8, 2045

    granted
  17. US 12297465

    CBLB endonuclease variants, compositions, and methods of use

    REGENERON PHARMACEUTICALS, INC. · Granted May 13, 2025 · Expires May 8, 2045

    granted
  18. US 12297257

    Multispecific antigen-binding molecules and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted May 13, 2025 · Expires May 8, 2045

    granted
  19. US 12291559

    Compositions and methods for treating cancer

    REGENERON PHARMACEUTICALS, INC. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  20. US 12291560

    Dimerizing agent regulated immunoreceptor complexes

    REGENERON PHARMACEUTICALS, INC. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  21. US 12291571

    Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody

    REGENERON PHARMACEUTICALS, INC. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  22. US 12281173

    Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in combination with an ANGPTL3 inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  23. US 12280124

    Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  24. US 12280093

    Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic retinopathy

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted